131 related articles for article (PubMed ID: 16965395)
41. Diagnostic Value of Glucose Transporter 1 (GLUT-1) Expression in Nested Variant of Urothelial Carcinoma.
Boyaci C; Behzatoğlu K
Turk Patoloji Derg; 2019; 35(1):22-27. PubMed ID: 30035295
[TBL] [Abstract][Full Text] [Related]
42. Oncoprotein changes in the flat lesions with atypia and invasive neoplasms of the urinary bladder.
Kee KH; Lee MJ; Ro JY
Oncol Rep; 2001; 8(3):579-83. PubMed ID: 11295084
[TBL] [Abstract][Full Text] [Related]
43. Epidermal growth factor receptor expression in pre-invasive and early invasive bronchial lesions.
Meert AP; Verdebout JM; Martin B; Ninane V; Feoli F; Sculier JP
Eur Respir J; 2003 Apr; 21(4):611-5. PubMed ID: 12762344
[TBL] [Abstract][Full Text] [Related]
44. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines.
Tomlinson DC; L'Hôte CG; Kennedy W; Pitt E; Knowles MA
Cancer Res; 2005 Nov; 65(22):10441-9. PubMed ID: 16288035
[TBL] [Abstract][Full Text] [Related]
45. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth.
Cheng J; Huang H; Zhang ZT; Shapiro E; Pellicer A; Sun TT; Wu XR
Cancer Res; 2002 Jul; 62(14):4157-63. PubMed ID: 12124355
[TBL] [Abstract][Full Text] [Related]
46. Urinary bladder biopsy with denuded mucosa: denuding cystitis-cytopathologic correlates.
Parwani AV; Levi AW; Epstein JI; Ali SZ
Diagn Cytopathol; 2004 May; 30(5):297-300. PubMed ID: 15108225
[TBL] [Abstract][Full Text] [Related]
47. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
[TBL] [Abstract][Full Text] [Related]
48. Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
Kim YS; Kim K; Kwon GY; Lee SJ; Park SH
BMC Urol; 2018 Jul; 18(1):68. PubMed ID: 30064409
[TBL] [Abstract][Full Text] [Related]
49. Flat intraepithelial lesions of the urinary bladder.
Cheng L; Cheville JC; Neumann RM; Bostwick DG
Cancer; 2000 Feb; 88(3):625-31. PubMed ID: 10649257
[TBL] [Abstract][Full Text] [Related]
50. H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases.
Castillo-Martin M; Collazo Lorduy A; Gladoun N; Hyun G; Cordon-Cardo C
J Pediatr Urol; 2016 Apr; 12(2):91.e1-7. PubMed ID: 26522772
[TBL] [Abstract][Full Text] [Related]
51. Lewis(y) antigen (blood group 8, BG8) is a useful marker in the histopathological differential diagnosis of flat urothelial lesions of the urinary bladder.
Gunia S; Kakies C; May M; Koch S; Erbersdobler A
J Clin Pathol; 2011 Aug; 64(8):672-6. PubMed ID: 21512109
[TBL] [Abstract][Full Text] [Related]
52. [Update on FGFR3 mutation and multiple regional epigenetic silencing (MRES) phenotype in urothelial carcinogenesis].
Masson-Lecomte A; Vordos D; de la Taille A; Neuzillet Y; Radvanyi F; Allory Y
Prog Urol; 2013 Feb; 23(2):96-8. PubMed ID: 23352301
[TBL] [Abstract][Full Text] [Related]
53. Diagnosis of urothelial carcinoma in situ using blue light cystoscopy and the utility of immunohistochemistry in blue light-positive lesions diagnosed as atypical.
Pederzoli F; Murati Amador B; Samarska I; Lombardo KA; Kates M; Bivalacqua TJ; Matoso A
Hum Pathol; 2019 Aug; 90():1-7. PubMed ID: 31071342
[TBL] [Abstract][Full Text] [Related]
54. Pseudocarcinomatous urothelial hyperplasia of the bladder: clinical findings and followup of 70 patients.
Kryvenko ON; Epstein JI
J Urol; 2013 Jun; 189(6):2083-6. PubMed ID: 23228381
[TBL] [Abstract][Full Text] [Related]
55. Prostate tumor overexpressed 1 expression in invasive urothelial carcinoma.
Rausch S; Hennenlotter J; Scharpf M; Teepe K; Kühs U; Aufderklamm S; Bier S; Mischinger J; Gakis G; Stenzl A; Schwentner C; Todenhöfer T
J Cancer Res Clin Oncol; 2016 May; 142(5):937-47. PubMed ID: 26746655
[TBL] [Abstract][Full Text] [Related]
56. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
[TBL] [Abstract][Full Text] [Related]
57. Activation of extracellular regulated kinases (ERK1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-Raf gene mutations.
Karlou M; Saetta AA; Korkolopoulou P; Levidou G; Papanastasiou P; Boltetsou E; Isaiadis D; Pavlopoulos P; Thymara I; Thomas-Tsagli E; Patsouris E
Pathology; 2009; 41(4):327-34. PubMed ID: 19404844
[TBL] [Abstract][Full Text] [Related]
58. [Histologic and cytologic aspects of urothelial atypia (dysplasia)].
Helpap B; Bödeker J; Pfitzenmaier N
Pathologe; 1985 Nov; 6(6):292-7. PubMed ID: 4088975
[No Abstract] [Full Text] [Related]
59. Targeted Next-Generation Sequencing of Flat Urothelial Lesions Reveals Putative Pathobiological Pathways, Potential Biomarkers, and Rational Therapeutic Targets.
Musangile FY; Matsuzaki I; Iwamoto R; Sagan K; Nishikawa M; Mikasa Y; Takahashi Y; Kojima F; Hara I; Murata SI
Mod Pathol; 2023 May; 36(5):100120. PubMed ID: 36812689
[TBL] [Abstract][Full Text] [Related]
60. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
Moussa M; Omran Z; Nosseir M; Lotfy A; Swellam T
APMIS; 2009 Jan; 117(1):45-52. PubMed ID: 19161536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
